Impact of family history of cancer on the incidence of mutation in epidermal growth factor receptor gene in non-small cell lung cancer patients

Lung Cancer

Volumn 81, Issue 2, 2013, Pages 162-166

  He, Yayi ^a   Li, Shuai ^a   Ren, Shengxiang ^a   Cai, Weijing ^a   Li, Xuefei ^a   Zhao, Chao ^a   Li, Jiayu ^a   Chen, Xiaoxia ^a   Gao, Guanghui ^a   Li, Wei ^a   Zhou, Fei ^a   Zhou, Caicun ^a  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Epidermal growth factor receptor; Family history of cancer; Family history of lung cancer; Incidence; Mutation; Non small cell lung cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CHINESE; FAMILY HISTORY; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

EPIDERMAL GROWTH FACTOR RECEPTOR; FAMILY HISTORY OF CANCER; FAMILY HISTORY OF LUNG CANCER; INCIDENCE; MUTATION; NON-SMALL CELL LUNG CANCER;

CARCINOMA, NON-SMALL-CELL LUNG; FAMILY HEALTH; FEMALE; GENES, ERBB-1; HUMANS; INCIDENCE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; MUTATION RATE;

EID: 84879883077     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.05.004     Document Type: Article

References (39)

1. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127:2893-2917.
2. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
3. Giaccone G., Gallegos Ruiz M., Le Chevalier T., Thatcher N., Smit E., Rodriguez J.A., et al. Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study. Clin Cancer Res 2006, 12:6049-6055.
4. Zhou C., Wu Y.L., Chen G., Feng J., Liu X.Q., Wang C., et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011, 12:735-742.
5. Lee J.K., Kim T.M., Koh Y., Lee S.H., Kim D.W., Jeon Y.K., et al. Differential sensitivities to tyrosine kinase inhibitors in NSCLC harboring EGFR mutation and ALK translocation. Lung Cancer 2012, 77:460-463.
6. Gao G., Ren S., Li A., Xu J., Xu Q., Su C., et al. Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is effective as first-line treatment of advanced non-small-cell lung cancer with mutated EGFR: a meta-analysis from six phase III randomized controlled trials. Int J Cancer 2012, 131:E822-E829.
7. Carbone D.P., Ding K., Roder H., Grigorieva J., Roder J., Tsao M.S., et al. Prognostic and predictive role of the VeriStrat plasma test in patients with advanced non-mall-cell lung cancer treated with erlotinib or Placebo in the NCIC Clinical Trials Group BR.21 Trial. J Thorac Oncol 2012, 7:1653-1660.
8. Zhou S., Ren S., Yan L., Zhang L., Tang L., Zhang J., et al. Clinical efficacy of erlotinib in patients previously treated for advanced non-small cell lung cancer. Respirology 2009, 14:709-715.
9. Thatcher N., Chang A., Parikh P., Rodrigues Pereira J., Ciuleanu T., von Pawel J., et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005, 366:1527-1537.
10. Bronte G., Rizzo S., La Paglia L., Adamo V., Siragusa S., Ficorella C., et al. Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma. Cancer Treat Rev 2010, 36(Suppl. 3):S21-S29.
11. Zhu C.Q., da Cunha Santos G., Ding K., Sakurada A., Cutz J.C., Liu N., et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR 21. J Clin Oncol 2008, 26:4268-4275.
12. Sone T., Kasahara K., Kimura H., Nishio K., Mizuguchi M., Nakatsumi Y., et al. Epidermal growth factor receptor mutations and gene amplification in nonsmall cell lung cancer: molecular analysis of IDEAL/INTACT gefitinib trials. J Clin Oncol 2005, 23:8081-8092.
13. Eberhard D.A., Johnson B.E., Amler L.C., Goddard A.D., Heldens S.L., Herbst R.S., et al. Mutations in the epidermal growth factor receptor and KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005, 23:5900-5909.
14. Mak R.H., Doran E., Muzikansky A., Kang J., Neal J.W., Baldini E.H., et al. Outcomes after combined modality therapy for EGFR-mutant and wild-type locally advanced NSCLC. Oncologist 2011, 16:886-895.
15. Goto K., Ichinose Y., Ohe Y., Yamamoto N., Negoro S., Nishio K., et al. Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer. J Thorac Oncol 2012, 7:115-121.
16. Inoue A., Suzuki T., Fukuhara T., Maemondo M., Kimura Y., Morikawa N., et al. Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol 2006, 24:3340-3346.
17. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall-cell lung cancer to gefitinib. New Engl J Med 2004, 350:2129-2139.
18. Paez J.G., Jänne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
19. Luo Y.H., Wu C.H., Wu W.S., Huang C.Y., Su W.J., Tsai C.M., et al. Association between tumor epidermal growth factor receptor mutation and pulmonary tuberculosis in patients with adenocarcinoma of the lungs. J Thorac Oncol 2012, 7:99-305.
20. Shigematsu H., Lin L., Takahashi T., Nomura M., Suzuki M., Wistuba I.I., et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005, 97:339-346.
21. Kosaka T., Yatabe Y., Endoh H., Kuwano H., Takahashi T., Mitsudomi T. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 2004, 64:8919-8923.
22. Li X., Hemminki K. Familial multiple primary lung cancers: a population-based analysis from Sweden. Lung Cancer 2005, 47:301-307.
23. Lindor N.M., Greene M.H. The concise handbook of family cancer syndromes, Mayo Familial Cancer Program. J Natl Cancer Inst 1998, 90:1039-1071.
24. Bell D.W., Gore I., Okimoto R.A., Godin-Heymann N., Sordella R., Mulloy R., et al. Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nat Genet 2005, 37:1315-1316.
25. Ohtsuka K., Ohnishi H., Kurai D., Matsushima S., Morishita Y., Shinonaga M., et al. Familial lung adenocarcinoma caused by the EGFR V843I germ-line mutation. J Clin Oncol 2011, 29:e191-e192.
26. Coté M.L., Liu M., Bonassi S., Neri M., Schwartz A.G., Christiani D.C., et al. Increased risk of lung cancer in individuals with a family history of the disease: a pooled analysis from the International Lung Cancer Consortium. Eur J Cancer 2012, 48:1957-1968.
27. Mai P.L., Garceau A.O., Graubard B.I., Dunn M., McNeel T.S., Gonsalves L., et al. Confirmation of family cancer history reported in a population-based survey. J Natl Cancer Inst 2011, 103:788-797.
28. Ren S., Kuang P., Zheng L., Su C., Li J., Li B., et al. Analysis of driver mutations in female non-smoker Asian patients with pulmonary adenocarcinoma. Cell Biochem Biophys 2012, 64:155-160.
29. Ren S., Chen X., Kuang P., Zheng L., Su C., Li J., et al. Association of EGFR mutation or ALK rearrangement with expression of DNA repair and synthesis genes in never-smoker women with pulmonary adenocarcinoma. Cancer 2012, 118:5588-5594.
30. Xue C., Hu Z., Jiang W., Zhao Y., Xu F., Huang Y., et al. National survey of the medical treatment status for non-small cell lung cancer (NSCLC) in China. Lung Cancer 2012, 77:371-375.
31. Mok T.S., Wu Y.L., Thongprasert S., Yang C.H., Chu D.T., Saijo N., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957.
32. Tiseo M., Gelsomino F., Boggiani D., Bortesi B., Bartolotti M., Bozzetti C., et al. EGFR and EML4-ALK gene mutations in NSCLC: a case report of erlotinib-resistant patient with both concomitant mutations. Lung Cancer 2011, 71:241-243.
33. Albain K.S., Belani C.P., Bonomi P., O'Byrne K.J., Schiller J.H., Socinski M. PIONEER: a phase III randomized trial of paclitaxel poliglumex versus paclitaxel in chemotherapy-naive women with advanced-stage non-small-cell lung cancer and performance status of 2. Clin Lung Cancer 2006, 7:417-419.
34. Breyer J.P., Avritt T.G., McReynolds K.M., Dupont W.D., Smith J.R. Confirmation of the HOXB13 G84E germline mutation in familial prostate cancer. Cancer Epidemiol Biomarkers 2012, 21:1348-1353.
35. Jalkh N., Nassar-Slaba J., Chouery E., Salem N., Uhrchammer N., Golmard L., et al. Prevalence of BRCA1 and BRCA2 mutations in familial breast cancer patients in Lebanon. Hered Cancer Clin Pract 2012, 10:7.
36. Gaughan E.M., Cryer S.K., Yeap B.Y., Jackman D.M., Costa D.B. Family history of lung cancer in never smokers with non-small-cell lung cancer and its association with tumors harboring EGFR mutations. Lung Cancer 2012, [Epub ahead of print].
37. Amos C.I., Pinney S.M., Li Y., Kupert E., Lee J., de Andrade M.A., et al. A susceptibility locus on chromosome 6q greatly increases lung cancer risk among light and never smokers. Cancer Res 2010, 70:2359-2367.
38. Shih J.Y., Gow C.H., Yu C.J., Yang C.H., Chang Y.L., Tsai M.F., et al. Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer. Int J Cancer 2006, 118:963-969.
39. Leone F., Cavalloni G., Pignochino Y., Sarotto I., Ferraris R., Piacibello W., et al. Somatic mutations of epidermal growth factor receptor in bile duct and gallbladder carcinoma. Clin Cancer Res 2006, 12:1680-1685.